Unveiling of the lab
According to Merck's press release, the facilities at the lab were built to provide services and application assistance to the pharmaceutical industry, for classic pharmaceutical clients working on solid dose formulations.
In his inaugural remarks, Dr Claus-Dieter Boedecker, MD and head, Merck Millipore India, highlighted the need for the new facility. "India is one of the largest exporters of pharmaceutical products to North America and the European region. Between 2009 and 2013, exports from India registered an average growth of 24 percent; almost unaffected by the overall economic situation. India also has the highest number of US FDA approved facilities outside the US, of which, most have approvals from authorities in Europe, Canada and Australia."
"The quality standards achieved by Indian pharmaceutical companies, however, have been overshadowed by the recent spate of quality concerns. These could adversely affect export performance going forward. Additionally, speed is of essence in the field of generics. With the new facility, Merck intends to deliver on both these parameters. Created with the needs of the industry in mind, the facilities provide service and application assistance to those working in solid dosage formulation," he opined further.
Merck's objective of setting up the Lab is primarily to assist clients, using advanced excipients from the Merck Millipore portfolio, with pre-formulation studies.
Mr Benoit Gourdier, head of sales, Asia, Process Solutions, summarized the lab's purpose,